Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ASH: Bortezomib Combats Non-Hodgkin's Lymphomas By Charlene Laino SAN DIEGO, CA -- December 8, 2004 -- The proteasome inhibitor bortezomib appears to be effective for the treatment of patients with a variety of nonHodgkin's lymphomas, a phase 2 study suggests. The drug appears to particularly benefit patients with mantle cell and follicular lymphomas, reported Owen A. O'Connor, MD, PhD, medical oncologist, department of medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. In 32 patients with mantle cell lymphoma, the response rate was 55%, Dr. O'Connor reported here on December 6th at the American Society of Hematology 46th Annual Meeting. Half of the patients had a complete response, and among the responders, progression-free survival was nearly 1 year. In 20 patients with follicular lymphoma, the response rate was 60%, including 1 complete response and 1 unconfirmed complete response, Dr. O'Connor reported. In these patients, the median progression-free survival has not yet been reached. "These were all heavily pretreated patients so we wouldn't expect such a good response," he said. But only 1 of 5 patients with small lymphocytic lymphoma had a partial remission, the study showed. The remaining patients, who suffered from marginal zone lymphoma, also went into partial remission. To date, over 60 nonHodgkin's lymphoma patients have been treated with an average of 4 cycles of treatment in the ongoing study, Dr. O'Connor said. Bortezomib was administered at doses of 1.5 mg/m2 to the patients on days 1, 4, 8, and 11 of the 21-day cycles. The most common grade 3 toxicity was lymphopenia; there were no grade 4 toxicities. Three patients developed grade 3 sensory neuropathy. "Ours and other studies clearly suggest that certain kinds of nonHodgkin's lymphoma are more sensitive to bortezomib," Dr. O'Connor said. "Clearly, mantle cell and follicular lymphomas are 2 of them." [Presentation title: A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin's Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition. Abstract 607] E-mail this page to a friend or colleague! To print, use this version